title: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
abstract: BACKGROUND
  Pseudomyxoma peritonei (PMP) is a rare and fatal disease for which no standard treatment has been established. Encouraging results have been recently reported with the combination of cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC).
  
  
  METHODS
  Seventy-five patients with PMP underwent CRS and closed abdomen HIPEC with mytomicin-C and cis-platinum over 10 years at a single institution. Potential clinicopathological prognostic variables were tested using multivariate analysis.
  
  
  RESULTS
  Optimal cytoreduction (residual tumor nodules < or = 2.5 mm) was performed in 72 patients (96%). Operative mortality was 1%. Five-year overall (OS) and progression-free (PFS) survival were 78.3% and 31.1% in the overall series, respectively. Optimal CRS, no previous systemic chemotherapy and low histological aggressiveness were independent predictors of better OS and PFS using multivariate analysis.
  
  
  CONCLUSIONS
  Favourable outcome after CRS and HIPEC can be expected in patients affected by PMP variants with low histological aggressiveness, undergoing optimal surgical cytoreduction and with no pre-operative systemic chemotherapy.
authors.affiliation: Department of Surgery, National Cancer Institute, Milan, Italy. marcello.deraco@istitutotumori.mi.it
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kusamura
authors.forename: Barbara
authors.initials: B
authors.lastname: Laterza
authors.forename: Miriam
authors.initials: M
authors.lastname: Favaro
authors.forename: Luca
authors.initials: L
authors.lastname: Fumagalli
authors.forename: Pasqualina
authors.initials: P
authors.lastname: Costanzo
authors.forename: Dario
authors.initials: D
authors.lastname: Baratti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000628:therapy*; D010537:Peritoneum / Q000601:surgery*; D011553:Pseudomyxoma Peritonei / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin